1. Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor
- Author
-
Sergio Cantoreggi, Solomon H. Snyder, Ajit G. Thomas, Jesse Alt, Silvia Sebastiani, Jie Zhang, Edward B. Massuda, Marigo Stathis, Camilo Rojas, Barbara S. Slusher, and Ed Rubenstein
- Subjects
Molecular interactions ,biology ,business.industry ,medicine.drug_class ,Nausea ,organic chemicals ,musculoskeletal, neural, and ocular physiology ,Palonosetron ,Antagonist ,Phases of clinical research ,Pharmacology ,5-HT3 receptor ,Anesthesiology and Pain Medicine ,nervous system ,polycyclic compounds ,biology.protein ,Vomiting ,Medicine ,Antiemetic ,heterocyclic compounds ,medicine.symptom ,business ,medicine.drug - Abstract
BACKGROUND:Palonosetron is a 5-HT3-receptor antagonist (5-HT3-RA) that has been shown to be superior to other 5-HT3-RAs in phase III clinical trials for the prevention of acute, delayed, and overall chemotherapy-induced nausea and vomiting. The improved clinical efficacy of palonosetron may be due
- Published
- 2008